CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Biotech Acquisition Co is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Biotech Acquisition Co
545 West 25Th Street, 20Th Floor
Phone: (858) 692-0539p:858 692-0539 NEW YORK, NY  10001  United States
This company ceased filing statements with the SEC on 2/14/2023.
On 2/1/2023, Biotech Acquisition Company announced that it will not implement the extension of the time period the Company has to complete an initial business combination as approved by its shareholders at an extraordinary general meeting of shareholders held on 1/19/2023 as a result of the investor being unable to deposit the requisite funds into the Company's trust account ("Trust Account") for the extension. As a result, the Company will dissolve and liquidate in accordance with the provisions of its Amended and Restated Memorandum and Articles of Association, as amended (the “Charter”) and will redeem all of the outstanding ordinary shares that were included in the units issued in its initial public offering (the “Public Shares”), at a per-share redemption price of approximately $10.15.
This company is no longer actively traded on any major stock exchange.
Business Summary
Biotech Acquisition Company is a blank check company. The Company is created for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or other similar business combination with one or more businesses. The Company focuses for a target business in the healthcare sector. It has no operations and has no revenues.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202212/31/2021YesYes---

Industries
SIC Code Description
6726 Unit investment trusts, face-amount certificate offices
6770 Blank checks

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer MichaelShleifer 48 9/1/2020 9/1/2020
Chief Financial Officer, Treasurer ThomasFratacci 45 9/1/2020 9/1/2020
Chief Operating Officer IvanJarry 44 9/1/2020 9/1/2020
4 additional Officers and Directors records available in full report.

Business Names
Business Name
BIOT
BIOTU

General Information
Outstanding Shares: 28,750,000 (As of 11/21/2022)
Shareholders: 2
Stock Exchange: NASD


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 3, 2024